参桃软肝片联合动脉化疗栓塞术治疗肝热血瘀型肝癌临床研究

Clinical Study on Shentao Ruangan Tablets Combined with Transcatheter Arterial Chemoembolization for Liver Function and Tumor Markers of Liver Cancer

目的:观察参桃软肝片联合动脉化疗栓塞术治疗对肝热血瘀型肝癌患者肝功能及肿瘤标志物的效果。方法:将肝热血瘀型肝癌患者80例随机分为对照组与观察组各40例。对照组给予吡柔比星(THP)+丝裂霉素C(MMC)+卡铂(CBP)+超化碘油作动脉化疗栓塞术治疗,观察组在对照组的基础上联合参桃软肝片进行治疗,疗程均为30 d。比较2组患者肝功能谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil)、白蛋白(Alb)、前白蛋白(PA)、乳酸脱氢酶(LDH)水平,以及肿瘤标志物甲胎蛋白(AFP)、α-L-岩藻糖苷酶(AFU)、癌胚抗原(CEA)变化情况。结果:治疗后,2组ALT、AST、LDH水平均较治疗前明显降低(P<0.05),且观察组各项指标均低于对照组(P<0.05)。治疗后,2组TBil水平较治疗前降低(P<0.05),Alb、PA水平较治疗前升高(P<0.05);且观察组各项指标改善较对照组更显著(P<0.05)。治疗后,2组AFP、AFU、CEA水平均较治疗前明显降低(P<0.05),且观察组各项指标均低于对照组(P<0.05)。2组治疗期间均未出现明显的不良反应。结论:参桃软肝片联合动脉化疗栓塞术治疗肝热血瘀型肝癌,可有效改善患者肝功能,在一定程度上抑制肿瘤细胞的生长,临床疗效安全可靠。

Objective:To observe the effect of Shentao Ruangan tablets combined with transcatheter arterial chemoembolization on liver function and tumor markers of patients with liver cancer.Methods:A total of 80 cases of patients with liver cancer were randomly divided into the control group and the observation group,40 cases in each group.The control group was treated with transcatheter arterial chemoembolization with pirarubicin(THP),mitomycin C(MMC),carboplatin(CBP)and lipiodol,and the observation group was additionally treated with Shentao Ruangan tablets based on the treatment of the control group.Both groups were treated for 30 days.The changes in levels of liver function including alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBil),albumin(Alb),prealbumin(PA)and lumbar disc herniation(LDH)as well as tumor markers including alpha-fetoprotein(AFP),α-L-fucosidase(AFU)and carcinoembryonic antigen(CEA)in the two groups were compared.Results:After treatment,the levels of ALT,AST and LDH in the two groups were significantly decreased when compared with those before treatment(P<0.05),and the indexes in the observation group were lower than those in the control group(P<0.05).After treatment,the TBil levels in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of Alb and PA were increased(P<0.05);the improvement of the above indexes in the observation group was more significant than that in the control group(P<0.05).After treatment,the levels of AFP,AFU and CEA in the two groups were significantly decreased when compared with those before treatment(P<0.05),and the above indexes in the observation group were lower than those in the control group(P<0.05).During treatment,there was no obvious adverse reaction in the two groups.Conclusion:Shentao Ruangan tablets combined with transcatheter arterial chemoembolization for liver cancer can improve the liver function and to some degree inhibit the growth of tumor cells with safe and reliable clinical effect.